ACOG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast ACOG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACOG is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

H.C. Wainwright

Buy

downgrade

$20 -> $18

2025-10-20

Reason

H.C. Wainwright

Price Target

$20 -> $18

2025-10-20

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Alpha Cognition to $18 from $20 and keeps a Buy rating on the shares after the sale of roughly 4.6M shares of common stock and approximately 949,000 pre-funded warrants to purchase common stock at a price of $6.25 per share earlier this month. The firm is trimming its 12-month price target to account for the equity dilution from the recent financing as well as revisions to its sales forecasts.

Valuation Metrics

The current forward P/E ratio for Alpha Cognition Inc (ACOG.O) is -5.12, compared to its 5-year average forward P/E of -5.48. For a more detailed relative valuation and DCF analysis to assess Alpha Cognition Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.48

Current PE

-5.12

Overvalued PE

-3.07

Undervalued PE

-7.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.71

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.37

Undervalued EV/EBITDA

-1.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

10.31

Current PS

7.64

Overvalued PS

16.51

Undervalued PS

4.10

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ACOG News & Events

Events Timeline

No data

News

7.5

2025-12-01Businesswire

Alpha Cognition to Participate in Virtual Fireside Chat on December 2, 2025

7.5

2025-12-01Newsfilter

Alpha Cognition to Participate in Virtual Fireside Chat on December 2, 2025

9.5

2025-11-14NASDAQ.COM

Alpha Cognition Inc. (ACOG) Announces Q3 Loss While Exceeding Revenue Projections

People Also Watch

Frequently Asked Questions

What is Alpha Cognition Inc (ACOG) stock price today?

The current price of ACOG is 6.53 USD — it has decreased -0.46 % in the last trading day.

What is Alpha Cognition Inc (ACOG)'s business?

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.

What is the price predicton of ACOG Stock?

What is Alpha Cognition Inc (ACOG)'s revenue for the last quarter?

Alpha Cognition Inc revenue for the last quarter amounts to 2.84M USD, decreased % YoY.

What is Alpha Cognition Inc (ACOG)'s earnings per share (EPS) for the last quarter?

Alpha Cognition Inc. EPS for the last quarter amounts to -0.08 USD, decreased -74.19 % YoY.

What changes have occurred in the market's expectations for Alpha Cognition Inc (ACOG)'s fundamentals?

The market is revising Downward the revenue expectations for Alpha Cognition Inc. (ACOG) for FY2025, with the revenue forecasts being adjusted by -6.72% over the past three months. During the same period, the stock price has changed by -6.98%.

How many employees does Alpha Cognition Inc (ACOG). have?

Alpha Cognition Inc (ACOG) has 52 emplpoyees as of January 10 2026.

What is Alpha Cognition Inc (ACOG) market cap?

Today ACOG has the market capitalization of 141.98M USD.